Search Results

You are looking at 161 - 170 of 502 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Brian Badgwell

Syst Rev 2013 : CD008415 . 15. Earle CC Maroun JA . Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials . Eur J Cancer 1999 ; 35 : 1059 – 1064

Full access

David S. Ettinger, Wallace Akerley, Gerold Bepler, Matthew G. Blum, Andrew Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis Jr., Thierry Jahan, Mohammad Jahanzeb, David H. Johnson, Anne Kessinger, Ritsuko Komaki, Feng-Ming Kong, Mark G. Kris, Lee M. Krug, Quynh-Thu Le, Inga T. Lennes, Renato Martins, Janis O'Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, George R. Simon, Scott J. Swanson, Douglas E. Wood, and Stephen C. Yang

-based therapy in a large group of patients with surgically resected NSCLC who participated in the International Adjuvant Lung Trial (IALT). In this study, only patients with low tumoral ERCC1 protein levels benefited from adjuvant chemotherapy (adjusted hazard

Full access

Sumanta K. Pal, Matthew I. Milowsky, and Elizabeth R. Plimack

approach to the disease. The utility of adjuvant chemotherapy after cystectomy remains highly contentious. Neoadjuvant therapy is also the subject of much discussion. Despite the existence of positive phase III data supporting this approach, it appears to

Full access

Elizabeth R. Kessler, Janet B. Kukreja, Christopher L. Geiger, and Stacy M. Fischer

, adjuvant therapy is occasionally considered. Studies examining adjuvant chemotherapy for bladder cancer have been limited by failure to accrue patients, and are thus underpowered for any definitive recommendations. These trials failed to fully accrue partly

Full access

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022

Featured Updates to the NCCN Guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Floor J. Backes, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Viola C. Chitiyo, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Gary Leiserowitz, Joyce Liu, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, Sanja Percac-Lima, Steven W. Remmenga, John Schorge, Daphne Stewart, Premal H. Thaker, Roberto Vargas, Andrea Wahner Hendrickson, Theresa L. Werner, Emese Zsiros, Mary A. Dwyer, and Lisa Hang

adjuvant chemotherapy regimens for patients with advanced age and/or comorbidities, an updated algorithm for LGSC based on emerging research and novel therapeutic agents, and revised language regarding tumor molecular analysis applications in ovarian cancer

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Ignacio Garrido-Laguna, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, and Deborah A. Freedman-Cass

, adjuvant chemotherapy. 10 Population and institutional studies have shown that adjuvant therapy may confer a survival advantage in some patients with resected colon cancer (eg, those with stage III or high-risk stage II disease). 11 – 14 Furthermore

Full access

Arti Hurria, Ilene S. Browner, Harvey Jay Cohen, Crystal S. Denlinger, Mollie deShazo, Martine Extermann, Apar Kishor P. Ganti, Jimmie C. Holland, Holly M. Holmes, Mohana B. Karlekar, Nancy L. Keating, June McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Stephen H. Petersdorf, Hope S. Rugo, Rebecca A. Silliman, William P. Tew, Louise C. Walter, Alva B. Weir III, and Tanya Wildes

associated with an increased risk of all-cause mortality (26.3% vs. 11.2%) among men with a history of coronary artery disease, CHF, or myocardial infarction after a median follow-up of 5.1 years. 45 In a randomized adjuvant chemotherapy trial of 3759

Full access

Scott Ramsey and Veena Shankaran

-related expenses, which may not only cause significant anxiety but also may limit their ability to pay for basic necessities such as food and housing. 1 In a recent population-based survey of patients with CRC receiving adjuvant chemotherapy, 38% experienced

Full access

Erica L. Mayer, Nancy U. Lin, and Harold J. Burstein

; 354 : 809 – 820 . 38. Piccart-Gebhart MJ Procter M Leyland-Jones B . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer . N Engl J Med 2005 ; 353 : 1659 – 1672 . 39. Slamon DJ Eiermann W Robert N . Phase

Full access

Judd E. Cummings, J. Andrew Ellzey, and Robert K. Heck

-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults . J Clin Oncol 2003 ; 18 : 3423 – 3430 . 6. Link MP Goorin MA Miser AW . The effect of adjuvant chemotherapy on relapse